Immunosuppression in autoimmune disease: the double-edged sword

Area of Science:

• Immunology
• Endocrinology
• Diabetology

Background:

• Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease affecting pancreatic beta cells.
• Diabetes-prone BioBreeding (BB) rats spontaneously develop IDDM, serving as a model for human type 1 diabetes.
• Current treatments focus on managing hyperglycemia, but preventing IDDM onset remains a challenge.

Purpose of the Study:

• To investigate the efficacy of prophylactic cyclosporin A (CsA) in preventing spontaneous IDDM in BB rats.
• To determine the optimal timing and duration for CsA administration to achieve permanent protection.
• To assess the impact of CsA on islet health and insulin production.

Main Methods:

• Administration of moderate-dose oral cyclosporin A (10 mg/kg/day) to diabetes-prone BB rats at different ages (6 weeks, 8-9 weeks) and durations.
• Monitoring of IDDM incidence, onset, and clinical symptoms in treated and control groups.
• Evaluation of pancreatic insulin content and islet morphology at various time points.

Main Results:

• Early CsA initiation (6 weeks) followed by prolonged treatment (until 21 weeks) completely prevented IDDM (0% vs. 46% in controls, p<0.001).
• Later initiation (8-9 weeks) or premature termination of CsA treatment resulted in partial or no protection.
• Lifelong protection was achieved only when CsA prophylaxis started early (minimal insulitis, normal insulin) and continued past the at-risk period.

Conclusions:

• Effective and permanent prevention of IDDM in BB rats requires early initiation of CsA treatment when pancreatic islets are healthy.
• Prolonged CsA administration, extending beyond the typical disease onset period, is crucial for sustained protection.
• This study highlights the potential of early immunosuppressive therapy for preventing autoimmune diabetes.